

MedGenome Labs launches clonoSEQ assay in India

14 July 2022 | News

The clonoSEQ test may effectively detect and monitor MRD in patients with certain types of blood cancer



Bengaluru-based MedGenome is offering Adaptive Biotechnologies' next-generation sequencing (NGS)-based clonoSEQ Assay to assess minimal residual disease (MRD) in patients with multiple myeloma (MM), chronic lymphocytic leukaemia (CLL) and B-cell acute lymphoblastic leukaemia (B-ALL).

The clonoSEQ test may effectively detect and monitor MRD in patients with certain types of blood cancer. It helps to detect MRD even at low levels offering a prognostic value to clinicians, helping them to assess how patients respond to treatment or if any change in disease management is required.

The test determines MRD at very low levels (*10⁻⁶ sensitivity*) as compared to other currently available assays for MRD detection and therefore imparts a benefit to a larger number of patients. The test identifies dominant immune cell clones at the time of high disease burden that can be monitored after the treatment to determine MRD.